Citigroup raised the price target for the Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock from ‘a Buy’ to ‘a Neutral’. The rating was released on June 09, 2023, according to finviz. We previously noted in another research note published on June 08, 2023 by Piper Sandler that downgraded the stock from an Overweight to a Neutral with a price target of $1 for RIGL stock. The research report from Cantor Fitzgerald has downgraded the stock from Overweight to Neutral, with a price target set at $1. The stock was initiated by B.